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ABSTRACT
Reconstitution of T cell immunity is absolutely critical for the effective control of virus-associated infectious complications in
hematopoietic stem cell transplant (HSCT) recipients. Coinfection with genetic variants of human cytomegalovirus (CMV) in
transplant recipients has been linked to clinical disease manifestation; however, how these genetic variants impact T cell im-
mune reconstitution remains poorly understood. In this study, we have evaluated dynamic changes in the emergence of genetic
variants of CMV in HSCT recipients and correlated these changes with reconstitution of antiviral T cell responses. In an analysis
of single nucleotide polymorphisms within sequences encoding HLA class I-restricted CMV epitopes from the immediate early 1
gene of CMV, coinfection with genetically distinct variants of CMVwas detected in 52% of patients. However, in spite of expo-
sure to multiple viral variants, the T cell responses in these patients were preferentially directed to a limited repertoire of HLA
class I-restricted CMV epitopes, either conserved, variant, or cross-reactive. More importantly, we also demonstrate that long-
term control of CMV infection after HSCT is primarily mediated through the efficient induction of stable antiviral T cell immu-
nity irrespective of the nature of the antigenic target. These observations provide important insights for the future design of an-
tiviral T cell-based immunotherapeutic strategies for transplant recipients, emphasizing the critical impact of robust immune
reconstitution on efficient control of viral infection.
IMPORTANCE
Infection and disease caused by human cytomegalovirus (CMV) remain a significant burden in patients undergoing hema-
topoietic stem cell transplantation (HSCT). The establishment of efficient immunological control, primarily mediated by
cytotoxic T cells, plays a critical role in preventing CMV-associated disease in transplant recipients. Recent studies have
also begun to investigate the impact genetic variation in CMV has upon disease outcome in transplant recipients. In this
study, we sought to investigate the role T cell immunity plays in recognizing and controlling genetic variants of CMV. We
demonstrate that while a significant proportion of HSCT recipients may be exposed to multiple genetic variants of CMV,
this does not necessarily lead to immune control mediated via recognition of this genetic variation. Rather, immune con-
trol is associated with the efficient establishment of a stable immune response predominantly directed against immuno-
dominant conserved T cell epitopes.
Allogeneic hematopoietic stem cell transplantation (HSCT)can be curative of life-threatening hematological malignan-
cies. However, due to the underlying immunodeficiency associ-
ated with HSCT and as a consequence of the immunosuppressive
regimes used to prevent graft-versus-host disease following
HSCT, infectious complications remain a significant burden to
the treatment modality. One significant infectious complication
following HSCT is caused by the ubiquitous pathogen human
cytomegalovirus (CMV) (1). Amember of the humanbetaherpes-
virus family, CMV is highly prevalent across populations and is
typically established as a lifelong asymptomatic infection in im-
munocompetent individuals. However, CMV is a leading cause of
viral complications in immunocompromised individuals (2). This
is particularly evident in the absence of CMV-specific immuno-
logical memory, including in CMV-seropositive HSCT recipients
(R) who receive a transplant from a seronegative donor (D)
and are at a higher risk of CMV reactivations and associated com-
plications, including enterocolitis and pneumonitis (3–5). Cur-
rent therapeutic strategies to control CMV reactivation in HSCT
recipients predominantly involve the preemptive administration
of ganciclovir to control CMV following detection of viral reacti-
vation (6). Through the use of immunological monitoring ap-
proaches, it is becoming apparent that the prevention of viral re-
activation and the long-term control of CMV infection are
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dependent upon the induction of robust and stable CMV-specific
immunological memory (7–10).
Recent studies have suggested that in addition to the efficiency
of immunological control of CMV, exposure to genotypically dis-
tinct variants of CMV may also have an impact on clinical out-
come following transplant. Genotypic analyses of surface CMV
glycoproteins have shown that immunocompromised patients,
bothHSCT and solid-organ transplant (SOT) recipients, are com-
monly coinfected with multiple genotypically distinct CMV vari-
ants (11, 12). It has also been demonstrated that SOT recipients
show an increased duration of viremia following reactivation of
multiple genotypic isolates (12), suggesting potentially reduced
immunological control following coinfection. Despite these ob-
servations, and considering the critical role T cell immunity plays
in the control of CMV, very little research has been performed that
specifically examines the impact of genetically distinct variants of
CMV on CMV-specific T cell immunity (13–15). While this is
particularly relevant for R/D HSCT patients, who are at in-
creased risk of CMV-associated complications, immune control
of CMV infection in R/D recipients could also be impacted by
exposure to distinct genetic viral variants of the recipient that are
not efficiently controlled by preexisting donor immunity. To ad-
dress the impact genetic variation has upon T cell immunity, we
focused upon the immunodominant immediate early 1 gene
(IE-1) of CMV, which has previously been shown to encode sig-
nificant genetic variation, including within immunodominant
CD8 T cell epitopes (13–15). Using pyrosequencing analysis to
identify genetic variation within IE-1, and IE-1-encoded epitope-
specific T cell analysis, we sought to determine the impact of ge-
netic variation and exposure to multiple viral variants on the in-
duction of CMV-specific T cell immunity in a cohort of HSCT
recipients.
MATERIALS AND METHODS
Study subjects. The study subjects were from a cohort of 46 allogeneic
HSCT recipients who were recruited on an immune monitoring study
approved by the Royal Brisbane andWomen’s Hospital Human Research
Ethics Committees (reference number 2006/192) (9, 16). All patients pro-
vided informed written consent. As described previously (9), all patients
were monitored for CMV viral load using the COBAS Amplicator CMV
Monitor test (RocheDiagnostics, Basel, Switzerland) andCMV-specific T
cell immunity using the QuantiFERON-CMV assay (Cellestis, Carnegie,
VIC, Australia). CMV reactivation was defined as the detection of 600
copies/ml of CMV DNA.
Detectionof IE-1 variantsusingpyrosequencing.DNAwas extracted
from plasma samples using the QIAamp DNA blood minikit (Qiagen,
USA). DNA PCR amplifications were performed using the PyroMark
PCR kit (Qiagen, USA) in a standard 25-l reaction for 45 cycles. PCR
amplification primers and the target sequences are as follows: IE1Start,
forward primer GGAGATGTGGATGGCTTGTATT, reverse primer GC
AGCCATTGGTGGTCTTA, and sequencing primer YATTCCTGTAGC
ACATATA (target sequence: MATCATCTTTCTCYTAAGTTCRTCC
TT); IE1Middle, forward primer TAAGACCACCAATGGCTGC, reverse
primer CATACAAGCGTCACTRGTGACCT, and sequencing primer AA
TCTTAAAKATYTTCTG (target sequence: GGMATAAGYCATAATCT
CATCAGGG); and IE1end, forward primer TYTGTCGRGTGCTGT
GCTGYT, reverse primer CACCAGCGGTGGCCAAAGTGTAG, and se-
quencing primers GRGTGCTGTGCTGYTA and AGGAGTCAGATGAG
GAAR (target sequences: TRTCTTAGAGGAGACTAGTGTGWTG
CTGG and AKGCTATTGYAGCCTACACTTTGGCC). The IUPAC
nucleotide code is shown for ambiguous sites. PCR cycling conditions
consisted of an initial 15min of denaturation at 95°C and 45 cycles of 95°C
for 30 s, 60°C for 30 s, and 72°C for 40 s. Pyrosequencing reactions were
performed according to the manufacturer’s instructions using a Qiagen
PyroMark Q24 system. Amplification products were washed in a series of
buffers, and single-stranded, biotinylated DNA products were hybridized
to sequencing primers in a 24-well plate and used at a final concentration
of 0.375 M in 20 l of annealing buffer. PCR amplification bias in pa-
tient samples was corrected through pyrosequencing analysis of DNA
from three well-characterized strains of human CMV (HCMV): AD169,
Toledo, and TB40E. The limit of detection in this system is 5%; therefore,
only values greater than this threshold were considered significant.
Establishment and maintenance of cell lines. Polyclonal T cell lines
specific for the IE-1-encoded variant epitopes listed in Table 2 and for
CMV-encoded conserved T cells, epitopes (HLA-A1-restricted VTEHD
TLLY and YSEHPTFTSQY, HLA-A2-restricted NLVPMVATV and FMD
ILTTCV, HLA-B7-restricted RPHERNGFTVL and TPRVTGGGAM, and
HLA-B8-restricted QIKVRVDMV)were generated following stimulation
of peripheral blood mononuclear cells (PBMC) with 1 g/ml of cognate
peptide. Polyclonal T cell cultures were maintained in growth medium
containing recombinant interleukin-2 (IL-2) and assessed for T cell spec-
ificity after 2 weeks.
Intracellular cytokine staining.Expanded polyclonal T cell lines were
stimulated with 1 g/ml of peptide and incubated for 4 h in the presence
of brefeldin A (BD Biosciences, USA). For functional-avidity assays, T
cells were stimulated in duplicate with 10-fold serial dilutions of peptide
(ranging from 1 g/ml to 0.1 ng/ml). Cells were then incubated with
peridinin chlorophyll protein (PerCP)-Cy5.5-labeled anti-CD8 (eBiosci-
ence, USA) and fluorescein isothiocyanate (FITC)-labeled anti-CD4 (BD
Biosciences, USA), fixed and permeabilized using a BDCytofix/Cytoperm
kit, and incubated with phycoerythrin (PE)-labeled anti-gamma inter-
feron (anti-IFN-; BDBiosciences). Cell acquisitionwas performed using
a BD LSRFortessa (BD Biosciences). Postacquisition analysis was per-
formed using FlowJo software (TreeStar, USA).
Statistical analysis. All statistical analysis was performed using Prism
6 software (GraphPad Software, USA). Statistical differences were as-
sessed using the nonparametric Mann-Whitney test. Data were consid-
ered statistical significant when the P value was0.05.
RESULTS
Dynamics of the emergence of genetic variants of CMV follow-
ing viral reactivation in HSCT recipients. Twenty-six patients
undergoing allogeneic HSCT were enrolled on this study follow-
ing informed consent (9, 16). The clinical characteristics of these
patients are listed in Table 1. All patients received a T cell-replete
bone marrow or granulocyte colony-stimulating factor (G-CSF)-
mobilized peripheral blood stem cell graft, and none had in vivo T
cell depletion. CMV-seropositive patients or patients who re-
ceived a transplant from a seropositive donor were treated pro-
phylactically with high-dose acyclovir from day 5 to day 28 or
until discharge and then with valganciclovir until day 100. Pa-
tients with CMV DNAemia in plasma of 600 copies/ml were
treated with ganciclovir at 5 mg/kg (of body weight) twice daily
for 14 days, followed by once-daily maintenance until plasma
DNAemia was600 copies/ml, or were treated with valganciclo-
vir at 900 mg twice daily followed by 900 mg once daily for main-
tenance. Foscarnet was used in patients who were nonresponsive
or displayed significant toxicity from ganciclovir. Of the 26 HSCT
recipients enrolled for this study, 17 had viral reactivation as de-
fined by CMV DNAemia of600 copies/ml. All of these patients
were CMV seropositive prior to transplant: 12 had a CMV-sero-
negative donor (characterized as R/D recipients), while the re-
maining five had a CMV-seropositive donor (characterized as
R/D recipients). Early CMV reactivation developed in 16 of
these patients, while 4 patients had late CMV reactivation, which
Smith et al.
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occurred beyond the first 100 days posttransplant. Two of the
late-CMV reactivation patients developed CMV-associated dis-
ease: one had colitis and one had enteritis. Fourteen of the 17
displayed anunstableCMV-specific immune response, as assessed
by the CMV-QuantiFERON assay, and characterized by a failure
to generate a stable CMV-specific IFN- response by 59 days post-
transplant (9). All nine patients included in the current study who
demonstrated CMV-immune reconstitution also were without
evidence of viral reactivation.
To delineate the impact of the emergence of genetic variants on
T cell immune reconstitution in this cohort of HSCT recipients,
we focused on eight HLA class I-restricted CD8 T cell epitopes
from the immediate early (IE-1) protein of CMV (Table 2). Three
novel epitopes were mapped during this study (Table 2), and
five epitopes have been previously described (17–21). Using the
GenBank database, we were able to identify a series of variant
sequences for each of these epitopes. We designed a pyrosequenc-
ing analysis to identify the single nucleotide polymorphisms
(SNPs) within the CMV-encoded CD8 T cell epitopes. Initially,
these SNP analyses were carried out at the peak of viral load for all
TABLE 1 Clinical characteristics of HSCT recipients included in this study
Code
Recipient/donor
serostatus HLA type
No. of episodes of
CMV reactivation
Maximal
CMV titer
Days posttransplant that the CMV
load was600 copies/ml
CMV
disease
Patients with CMV
reactivationa
04 R/D A2 A29 B44 B51 Cw1 4 10,000 60–70, 144–158, 189–195, 363–391 Yes: CMV
colitis
06 R/D A23 A26 B39 B51 Cw2 1 900 64–71 No
13 R/D A2 A29 B44 B62 Cw3 Cw16 2 12,000 33–67, 77–84 No
14 R/D A11 A31 B7 B60 6 120,000 46–55, 139–178, 192–196, 213–217,
249–269, 286–314
Yes: CMV
enteritis
16 R/D A2 A24 B15 B27 Cw2 Cw3 1 870 69 No
17 R/D A1 A24 B08 B39 Cw7 2 40,000 37, 44–68 No
19 R/D A2 A24 B44 Cw5 3 55,000 32–64, 73–80, 88–92 No
25 R/D A2 A3 B35 B62 Cw3 Cw10 2 2,400 59, 95–102 No
26 R/D A2 A33 B14 B15 Cw3 Cw8 3 4,100 35–60, 81–88, 273–277 No
28 R/D A2 A24 B44 Cw5 Cw6 1 6,800 46–67 No
30 R/D A2 A24 B13 B60 Cw3 Cw4 1 64,000 314–332 No
32 R/D A2 B13 B40 Cw3 Cw6 5 22,000 39, 49–63, 151–157, 179, 192–237 No
34 R/D A1 A33 B8 B14 Cw7 Cw8 1 2,000 57–64 No
38 R/D A1 A24 B41 B57 Cw6 Cw17 1 1,400 75–92 No
39 R/D A2 A29 B44 Cw5 1 6,900 45–62 No
44 R/D A2 A32 B18 B44 Cw5 Cw7 1 1,000 43–48 No
46 R/D A2 B27 B44 Cw2 Cw5 2 2,800 32–35, 53 No
Patients without CMV
reactivation
01 R/D A1 A3 B27 B60 Cw2 Cw3 NAb NA NA No
07 R/D A1 A2 B08 B15 Cw3 Cw7 NA NA NA No
15 R/D A3 A31 B7 B60 Cw3 Cw7 NA NA NA No
36 R/D A1 A2 B35 B62 Cw3 Cw4 NA NA NA No
37 R/D A2 A23 B15 B44 Cw4 Cw7 NA NA NA No
42 R/D A2 A23 B15 B44 Cw4 Cw7 NA NA NA No
43 R/D A1 A26 B44 B13 Cw7 NA NA NA No
45 R/D A1 A2 B37 B44 Cw5 Cw6 NA NA NA No
47 R/D A2 B7 B44 Cw5 Cw7 NA NA NA No
a CMV reactivation is defined as CMV DNAemia of600 copies/ml.
b NA, not applicable.
TABLE 2 List of IE-1 epitope variants used in this study
Epitope HLA restriction Sequence position Major epitope varianta Amino acid variant(s) (position) Reference(s)
KARAKKDELR A31 192–201 KARAKKDELK R/K (10) This study
ARAKKDELR B27 193–201 ARAKKDELK R/K (9) This study
DELRRKMMY B18, B44 198–206 DELKRKMIY R/K (4), M/I (8) 17
ELRRKMMYM B8 199–207 ELKRKMIYM R/K (3), M/I (7) 19
RRKMMYMYCR B27 201–210 KRKMIYMYCR R/K (1), M/I (5) This study
AYAQKIFKIL A23 248–257 TYSQKIFKIL A/T (1), A/S (3) 20, 21
VLEETSVML A2 316–324 YILEETSVML V/I (1 or 2) 18
EEAIVAYTL B18, B44 381–390 EDAIAAYTL E/D (2), V/A (5) 17
a Changes are indicated by bold type and underlining.
CMV Genetic Variation in HSCT Recipients
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HSCT recipients who showed CMV reactivation. The amino acid
residue at each variant position was extrapolated based upon the
nucleotide sequence. Data in Fig. 1 represent the proportion of
recipients showing either one or both amino acids at each posi-
tion. Data were corrected for error rates at each position as out-
lined in Materials and Methods. Although we observed bias in
amino acid usage at certain positions, we noted that the preferen-
tial usages of particular amino acid residues were similar in the
R/D (Fig. 1A) and the R/D (Fig. 1B) cohorts. This analysis
also revealed that a high proportion of HSCT recipients had mul-
tiple IE-1 variants following reactivation, whereby 6 to 40% of the
samples demonstrated both variant amino acids and 9 of 17HSCT
recipients (5 of 12 R/D and 2 of 5 R/D) showed definitive
evidence of mixed infection characterized by the concurrent de-
tection of both variant residues at least one position.
We subsequently assessed the stability of the viral variants over
time, using longitudinal plasma samples during viral reactivation
from 16 of the 17 HSCT recipients. Representative longitudinal
analysis of all SNPs assessed in individual patients is shown in Fig.
2. While some HSCT recipients, including both R/D and
R/D patients, showed very little change in the pattern of SNP
expression following detection of either predominantly single
variants (recipient 4) or multiple variants (recipient 17), other
HSCT recipients demonstrated changes in SNP frequency during
periods of viral reactivation. This is particularly evident for the
D/R patient 19.
Impact of coinfectionon theTcell kinetics.Wenext sought to
assess the impact of epitope variation and coinfection on IE-1-
specific T cell immunity. As the frequency of IE1-specific T cells
was too low in the majority of patients for direct ex vivo analysis,
PBMC from HSCT recipients showing evidence of viral reactiva-
tion were stimulated with all potentially HLA-matched variant
peptide epitopes (Table 2) and then cultured in vitro for 2weeks in
the presence of IL-2. PBMC from nine HSCT recipients showing
immune reconstitution with no evidence of CMV reactivation
were also stimulated with HLA-matched variant peptide epitopes
(Table 2). As a control, PBMC were stimulated with at least two
conserved HLA-matched epitopes. Representative longitudinal
analysis from three of these patients overlaid with viral reactiva-
tion kinetics is shown in Fig. 3A to C. An overall summary of the
number of HSCT recipients tested for each epitope and the num-
ber of responding HSCT recipients is shown in Table 3. Interest-
ingly, these observations suggested that while some patients could
efficiently recognize multiple viral variants detected by pyrose-
quencing analysis (represented by patient 28 [Fig. 3B and E]),
others showed preferential recognition, in some instances tar-
geted against subdominant epitope variants. As evidenced in Fig.
3D, pyrosequencing analysis revealed that the IE-1 sequence in
recipient 17 at amino acid positions 201 and 205 was dominated
by the residues R and M, which would correspond to the ELRRK
MMYM epitope in HLA-B8 individuals. Despite this, recipient 17
only generated a T cell response against the subdominant ELKRK
MIYM variant (Fig. 3A). Interestingly, recipient 17 also showed
the absence of a detectable response against the immunodomi-
nant conserved T cell epitope, VTEHDTTLY, during viral reacti-
vation and failed to generate a T cell response against the domi-
nant ELRRKMMYM variant even after resolution of viral
infection. Similar observations were made for recipient 44 (Fig.
3F), for whom we could detect sequences encoding both of the
HLA-B44 variants but were unable to detect a response against the
DELKRKMIY variant during viral reactivation. Interestingly,
these observations were also made for other HLA-B44-positive
HSCT recipients for both of theHLA-B44-restricted epitopes (Ta-
ble 3). This was particularly evident for the EDAIAAYTL variant,
which could be detected in 6 of 7 HLA-B44-positive HSCT recip-
ients but failed to induce a significant T cell response in any recip-
ient. It is important to mention that we initially aimed to perform
longitudinal analysis throughout the course of viral reactivation in
all patients; however, in themajority of CMV reactivation patients
tested, we were unable to see CMV-specific immune reconstitu-
tion until convalescence. The peak CD8 T cell response of each
patient to each epitope tested is presented in Table S1 in the sup-
plemental material.
To further assess the recognition of epitope variants in our
recipient cohort, cultured T cells from all HSCT recipients were
stimulated with serial dilutions of both the cognate and variant
peptide and assessed for the production of IFN-. The 50% effec-
tive concentration (EC50)was then calculated based upon the con-
centration of peptide required to induce 50% of maximal IFN-
production. Representative analysis following recall of a YILEET
SVML-stimulated T cell culture with 10-fold serial dilutions of the
VLEETSVML and YILEETSVML epitope variants is shown in Fig.
4A. While T cells specific for HLA-A2-restricted epitopes (VLEE
FIG 1 Pyrosequencing analysis of the IE-1 sequence variants in HSCT recip-
ients. DNA was extracted from plasma samples of 17 HSCT recipients during
CMV reactivation. Following DNA PCR amplification, pyrosequencing anal-
ysis of the panel of SNPs was performed as outlined inMaterials andMethods.
The nucleotide data were extrapolated to determine the proportion of each
amino acid residue for the 8 positions tested. (A) Data represent the propor-
tion of R/D recipient samples encoding either a dominant single amino acid
residue at each position or both amino acid residues at each position. (B) Data
represent the proportion of R/D recipient samples encoding either a dom-
inant single amino acid residue at each position or both amino acid residues at
each position.
Smith et al.
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TSVML and YILEETSVML) consistently recognized these vari-
ants with similar efficiencies (Fig. 3B and C), cross-reactivity to-
ward the HLA-B8 epitopes, ELRRKMMYM and ELKRKMIYM,
was patient dependent, characterized by preference for a single
variant in some individuals (recipient 17) and cross-reactive in
others (recipients 34 and 37) (Fig. 4D and E).We saw no evidence
of cross-reactivity in T cells specific for the two B44-restricted
epitopes, DELRRKMMY and EEAIVAYTL, which displayed pref-
erential bias for a single variant, irrespective of evidence for expo-
sure to multiple variants (Fig. 4F and G). These observations fur-
ther demonstrate that exposure tomultiple viral variants does not
automatically lead to the efficient induction of cross-reactive T
cell immunity and that repertoire “holes” may exist across genet-
ically unrelated individuals.
Impact of exposure to multiple viral variants on viral con-
trol. We next sought to determine if the reconstitution of the
CMV-specific T cell response directed toward both variant IE-1
and/or conserved epitopes was associated with viral reactivation.
We compared the frequencies of CD8 T cells specific for both
IE-1 variant epitopes and conserved epitopes early (90 to 106
days) and late (180 days) posttransplant in HSCT recipients
with and without evidence of reactivation. Pairwise analysis of the
frequency of all detectableCMV-specificT cell responses early and
late posttransplant demonstrated that HSCT recipients with evi-
dence of viral reactivation (Fig. 5A) showed less stability in their T
cell responses than HSCT recipients without reactivation (Fig.
5B). To contrast the responses in R/D and R/D patients, we
assessed the fold change in the responses early and late posttrans-
plant in these two cohorts. While R/D recipients with reactiva-
tion showed significantly greater fold differences in the frequency
of CMV-specific T cells between early and late responses than did
R/D recipients with no reactivation, we did not see significant
differences in the R/D patients (Fig. 5C). To further assess the
impact of reactivation with multiple viral variants on viral con-
trol, we compared (i) the number of viral reactivations, (ii) the
peak viral load, and (iii) duration of the first viral reactivations
in HSCT R/D and R/D recipients with evidence of single
or multiple variants in their peripheral blood. These analyses
revealed no significant differences in the number of viral reac-
tivations (Fig. 5D), in the peak viral load (Fig. 5E), or in the
duration of reactivation (Fig. 5F) from patients with and with-
out evidence of multiple viral variants. These observations sug-
gest that while the induction of variant specific immunity may
play a role in the control of viral reactivation following reacti-
vation with multiple variants of CMV, the capacity to induce
stable CMV-specific immune reconstitution to either con-
served epitopes or via cross-reactive responses was more rele-
vant for the efficient control of CMV reactivation following
HSCT.
FIG 2 Longitudinal pyrosequencing analysis in HSCT recipients. Longitudinal pyrosequencing analysis was performed with HSCT patients from whommore
than a single time point of viral reaction was available. Each data line represents individual SNPs over time following a single or multiple rounds of viral
reactivation.
CMV Genetic Variation in HSCT Recipients
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DISCUSSION
Observations over the last 2 decades, particularly with human
immunodeficiency virus (HIV) and other retroviruses, have
demonstrated that genetic variation in viral sequences can have
a significant impact upon long-term viral control (22–24). Un-
like the case with these rapidly mutating retroviruses, T cell
immunity to CMV and other human herpesviruses has typi-
cally been shown to be stable, with little change in the T cell
repertoire (25–27). However, there is emerging evidence that
multiple CMV variants can be found in a single individual that
encode a significant amount of genetic diversity (28, 29). In this
study, we sought to assess the impact of genetic diversity and
exposure to multiple CMV variants on immunomediated con-
trol of CMV in HSCT recipients. These analyses revealed that
while a large proportion of HSCT recipients undergoing viral
reactivation carrymultiple viral variants, the long-term control
of CMV infection is primarily mediated through the efficient
induction of stable reconstitution of T cell immunity irrespec-
tive of the nature of the antigenic target. However, these obser-
vations also indicate that the impact of CMV genetic variation
on immunity is complex, and larger sample sizes with greater
sequencing depth will likely be require to thoroughly delineate
the impact genetic variation has upon the immunological con-
trol of CMV.
FIG 3 Kinetics of variant-specific T cell activation following viral reactivation in HSCT transplant recipients. Longitudinal PBMC fromHSCT recipients during
and after CMV reactivation were stimulated with HLA-matched IE-1-encoded variant peptide epitopes and control nonvariant peptides and then cultured in
vitro for 2 weeks in the presence of IL-2. Twoweeks later, T cell cultures were recalled with cognate peptide and assessed for the intracellular expression of IFN-.
Representative data from three HSCT recipients overlaid with the kinetics of viral reactivation are shown. (A) PBMC from recipient 14 were assessed for T cell
responses on days 40, 47, 54, 68, 82, and 96 posttransplant. (B) PBMC from recipient 28 were assessed for T cell responses on days 41, 60, 67, 97, and 370
posttransplant. (C) PBMC from recipient 44were assessed for T cell responses ondays 48, 68, and 364 posttransplant. Representative data of the frequency of each
variant amino acid residue relevant to the T cell responses shown in panels A to C at the peak of viral reactivation are shown for recipient 17 (D), recipient 28 (E),
and recipient 44 (F). *, no response detected.
Smith et al.
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As a major viral complication that has arisen since the ad-
vent of HSCT, CMV can lead to significant morbidity and mor-
tality in immunocompromised patients (7). Complications
associated with CMV infection are most evident in an immu-
nologically naive setting; however, observations have shown
that exposure to CMV can still cause disease irrespective of
prior immunological exposure in immunocompromised indi-
viduals (3). It has been suggested that genotypic variation with
CMV and exposure to multiple genetic variants may play a role
in clinical outcome. Recent observations have demonstrated
that the detection of multiple CMV genotypes in transplant
recipients is common and can be associated with an increased
duration of viral reactivation (12). Although we also detected
evidence of multiple genetic variants of CMV in our cohort of
HSCT recipients, we did not see any evidence of an impact on
viral reactivation. However, it should be noted that previous
studies were carried out with predominantly SOT recipients
using genotypic analysis of surface glycoproteins, while our
observations were generated with a cohort of HSCT recipients
using genotypic analysis of IE-1. It could be speculated that
differences in these observations could be attributable to (i)
differences in immunogenicity/protection between glycopro-
teins and IE-1 targets, (ii) the different impact of coinfection in
SOT versus HSCT recipients, or (iii) the limited size of our
cohort.
We did observe an association between the stability of
CMV-specific T cell immunity in our R/D cohort and viral
reactivation. CMV-reactivation patients in this cohort were
less likely to have stable epitope specific T cell responses irre-
spective of the conserved or variant nature of the target epitope
than patients with no evidence of viral reactivation. These ob-
servations are consistent with previous studies, using different
immunological approaches, demonstrating the association be-
tween CMV reactivation in transplant patients and poor or
unstable CMV-specific T cell immunity (7, 9, 30, 31). Further-
more, the stability of this T cell response did not appear to be
influenced by the nature of viral reactivation. CMV reactiva-
tion with both multiple or single viral strain was similarly as-
sociated with unstable T cell responses. We were unable to see
a similar correlation between reactivation and T cell immunity
in our RD cohort. However, this cohort of RD patients
was small, impacting the ability to detect significant differences
and the potential influence of other factors, such as genetic
variation between the recipient and donor CMV isolates. It is
also important to appreciate that CMV-specific CD8 and
CD4 T cell immunity is directed against a diverse array of
antigens, and genetic variation within a single CMV gene may
have limited impact on overall immune control. While these
observations suggest that the induction of a robust T cell re-
sponse is more critical for immune control than the generation
of multivariant specific immunity, in some individuals we
could detect the induction of a non-cross-reactive T cell re-
sponse only during viral reactivation, tentatively suggesting
that in some instances an absence of cross-reactivity could be
affecting viral control.
Although we did not see any definitive evidence that the
TABLE 3 Summary of CMV-specific peptide epitope recognition by HSCT recipients
Peptide
sequencec
Reactivation No reactivation
No. of HLA-matched
recipients
No. of HLA-matched
recipients with
sequence detected
No. of
respondersa
No. of HLA-matched
recipients
No. of
respondersa
VLEETSVML 12 7 3 5 1
YILEETSVML 12 5 4 5 2
DELRRKMMY 7 5 2 4 0
DELKRKMIY 7 3 1 4 0
EEAIAVAYL 7 4 2 4 0
EDAIAAYTL 7 6 0 4 0
ELRRKMMYM 2 2 1 2 2
ELKRKMIYM 2 1 2 2 2
AYAQKIFKIL 1 0 1 1 0
TYSQKIFKIL 1 1 1 1 1
KARAKKDELR 1 1 0 1 0
KARAKKDELK 1 0 0 1 0
ARAKKDELK 1 1 1 1 0
ARAKKDELR 1 1 1 1 0
KRKMIYMCYR 1 0 0 1 1
RRKMMYMCYR 1 1 1 1 1
FMDILTTCV 12 NDb 5 5 0
NLVPMVATV 12 ND 8 5 3
RPHERNGFTVL 1 ND 1 1 1
TPRVTGGGAM 1 ND 1 1 1
VTEHDTLLY 3 ND 3 4 3
QIKVRVDMV 2 ND 1 1 1
YSEHPTFTSQY 0 ND 0 2 2
a Patients with5% of CD8 T cells producing IFN- following recall after 2 weeks of culture were considered responders.
b ND, not done.
c Underlining represents variant amino acids.
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reactivation of multiple variants impacted CMV disease, inter-
estingly, we did observe that some variant epitopes failed to
induce detectable T cell responses which were either cross-
reactive or variant-specific, despite their detection in a large
proportion of HSCT recipients (Table 3). This was particularly
evident for the B44-restricted epitope variant EDAIAAYTL, for
which we detected no T cells responses, despite the detection of
T cells specific for EEAIVAYTL variants in 50% of HSCT recip-
ients in which the variant sequences were detected. Previous
studies in a number of settings have shown that amino acid
sequence changes can restrict variant peptide recognition, of-
ten as a consequence of changes in major histocompatibility
complex (MHC) anchor residues that result in poor MHC
binding or due to restricted T cell repertoire diversity (32–34).
Given that the EDAIAAYTL amino acid sequence changes do
not occur in MHC anchor residues, our observations suggest
that these variant epitopes may have reduced immunogenicity
for other reasons, such as limitations in the T cell repertoire.
While the implications for these observations in the control of
viral reactivation are not clear, in settings of adoptive immu-
notherapy whereby donor-derived, autologous, or third-party
T cells are used (35–37), limited cross-reactivity against variant
epitopes could potentially limit the effectiveness of these T cells
for pathogen surveillance.
In conclusion, the observations in this study provide evi-
dence that exposure to multiple viral variants in an immuno-
FIG4 Functional-avidity analysis of IE-1 variant-specific T cell populations. Following in vitro expansion for 2weeks in the presence of cognate peptide and IL-2,
IE-1 epitope-specific T cells were incubated for 4 h with 10-fold serial dilutions of both the cognate peptide and the epitope variant. IFN- expression was then
assessed using an intracellular cytokine assay. The EC50was calculated based upon the peptide concentration required to induce activation in 50%of themaximal
number of IFN--producing cells. (A)Representative peptide titration fromYILEETSVML-stimulatedT cell cultures frompatient 47 recalledwithVLEETSVML
and YILEETSVML is shown. Data in bottom rows correspond to T cells stimulated ex vivo with VLEETSVML (B), YILEETSVML (C), ELRRKMMYM (D),
ELKRKMIYM (E), DELRRKMMY (F), and EEAIVAYTL (G). Color keys at the bottom of each row correspond to the cognate and variant peptides used to recall
the T cells response after 2 weeks in culture.
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compromised setting is common and does not necessarily lead
to the automatic induction of cross-reactive immunity. This
study also provides evidence that protection against genetically
distinct variants of CMV in infected individuals is not neces-
sarily dependent upon the induction of cross-reactive T cell
populations against variant epitopes but can be efficiently me-
diated via the recognition of conserved T cell epitopes. These
observations further demonstrate the importance of robust
stable immune reconstitution in the long-term control of CMV
following HSCT.
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